Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
On June 11, 2025, Disc Medicine, Inc., a pharmaceutical company valued at $1.87 billion, held its Annual Meeting of Stockholders, where several key proposals were voted upon. The company, formerly known as Gemini Therapeutics, Inc. and FS Development Corp., is registered in Delaware and headquartered in Watertown, Massachusetts. According to InvestingPro data, while the company maintains strong liquidity with more cash than debt, it currently trades above its Fair Value estimate.
During the meeting, shareholders elected three Class II directors: Georges Gemayel, Ph.D., Mark Chin, M.S., M.B.A., and Liam Ratcliffe, M.D., Ph.D. Each will serve a three-year term expiring in 2028. The voting results for their election were as follows: Gemayel received 30,122,499 votes for and 920,582 withheld, Chin received 30,847,995 votes for and 195,086 withheld, and Ratcliffe received 26,803,620 votes for and 4,239,461 withheld. All three faced 1,076,876 broker non-votes. The company’s stock has shown significant volatility, with a beta of 2.5, though it has delivered a strong 37% return over the past year.
Additionally, shareholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 30,801,342 votes for, 235,453 against, and 6,286 abstentions. They also recommended, on a non-binding advisory basis, that future advisory votes on executive compensation occur every year. The voting for this frequency was 30,860,482 for one year, 424 for two years, 176,183 for three years, and 5,992 abstentions.
Furthermore, the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 32,117,099 votes for, 2,370 against, and 488 withheld.
In light of these results, the board of directors has decided to hold advisory votes on executive compensation annually until the next required vote on the matter, anticipated to be at the 2031 annual meeting, or until the board decides otherwise.
This report is based on the official SEC filing of Disc Medicine, Inc. InvestingPro analysis reveals the company maintains a strong financial health score of GOOD, with analysts maintaining a Strong Buy consensus. For deeper insights into Disc Medicine’s financial metrics and growth potential, including 10+ additional ProTips and comprehensive analysis, explore the full Pro Research Report available on InvestingPro.
In other recent news, Disc Medicine reported positive data from its clinical programs at the European Hematology Association 2025 annual meeting in Milan. The company showcased long-term data from the HELIOS open-label extension study of bitopertin in erythropoietic protoporphyria, highlighting sustained reductions in protoporphyrin IX levels and improvements in quality of life measures. Disc Medicine plans to submit a New Drug Application for bitopertin in the second half of 2025. For DISC-0974, results from a Phase 1b trial in myelofibrosis anemia showed durable responses, with 50% of non-transfusion dependent patients achieving a sustained hemoglobin increase. The ongoing Phase 2 RALLY-MF trial is expected to provide initial data in the latter half of 2025. Additionally, results from a Phase 1 study of DISC-3405 indicated the drug’s ability to produce sustained reductions in serum iron levels, leading to the initiation of a Phase 2 trial in polycythemia vera. A separate study of DISC-3405 demonstrated significant inhibition of dietary iron uptake, supporting its potential use in iron overload conditions. These developments reflect Disc Medicine’s continued progress in advancing its treatment pipeline for hematologic diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.